aTyr rises as FDA aligns on late-stage lung disease study plan
BUZZ-aTyr rises as FDA aligns on late-stage lung disease study plan ** Shares of biotech firm aTyr Pharma ATYR.O rise 5.6% to $0.40 premarket
** Co says FDA agreed on the protocol for a planned late-stage study of efzofitimod in pulmonary sarcoidosis, an inflammatory lung disease that can scar the lungs
** Global study will enroll about 372 patients comparing the experimental drug with placebo
** Main goal is improved lung function; key secondary goal is better respiratory symptoms and quality of life
** Company expects to begin study-related activities in Q4 2026 and pursue US and European regulatory submissions
** Prior subgroup data showed clinically meaningful lung function benefits in pulmonary sarcoidosis patients with restrictive lung diseases
** Co says future development of efzofitimod will require additional funding through equity, debt, partnerships or licensing deals
** As of last close, stock down ~52% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan